Hypertension

Hypertension is a monthly peer-reviewed journal published by Lippincott Williams & Wilkins on behalf of the American Heart Association, founded in 1979 and devoted to blood pressure regulation, the pathophysiology of hypertension and its clinical treatment and prevention, with a 2025 Journal Impact Factor of 9.8 and a first quartile rank of seventh out of 100 titles in peripheral vascular disease《高血压》（Hypertension）是（Lippincott Williams & Wilkins）代表美国心脏协会（AHA）出版的月刊同行评审期刊，1979 年创刊，聚焦血压调节、高血压病理生理及其临床治疗与预防，2025 年影响因子为 9.8，在外周血管疾病类 100 种期刊中列第 7 位、居第一四分位。

Scope

• The journal states that it publishes scientific investigation of the highest quality in the broad field of blood pressure regulation and pathophysiology, clinical treatment and prevention of hypertension, and it encourages original articles on hypertension and related fields such as nephrology, endocrinology, neuroscience, vascular biology, physiology, pharmacology, cellular and molecular biology and genetics该刊声明刊发血压调节与病理生理、高血压临床治疗与预防这一广阔领域的最高水平研究，并欢迎同时涉及肾脏病学、内分泌学、神经科学、血管生物学、生理学、药理学、细胞与分子生物学及遗传学的原创论文。
• Its pages carry original manuscripts, invited review summaries, invited case-based reviews, recent study highlights, invited brief commentaries, scientific or technical tutorials, letters to the editor and reports of novel findings of unusual interest刊物体裁包括原创论文、约稿综述、约稿病例评述、研究亮点、约稿短评、科学或技术教程、致编者信，以及具有特殊意义的新发现报告。
• It is also an outlet for association scientific statements and council documents, among them the 2023 statement on cancer therapy-related hypertension prepared on behalf of the Council on Hypertension with the journals editor-in-chief as panel chair该刊同样用于发表美国心脏协会的科学声明与理事会文件，其中包括 2023 年由高血压理事会牵头、时任主编担任小组主席完成的癌症治疗相关高血压科学声明。
• It is a subscription title that also offers open access, and its work is addressed to cardiologists, endocrinologists, nephrologists, internists and primary care physicians as well as to physiologists, pharmacologists and molecular biologists该刊以订阅为主并另设开放获取选项，读者对象包括心脏科、内分泌科、肾脏科、内科与全科医师，以及生理学家、药理学家与分子生物学家。
• It has been covered by MEDLINE and PubMed from volume 1 number 1 of January/February 1979 and it is indexed in the Science Citation Index Expanded, Scopus, EMBASE, CINAHL, Current Contents, Biological Abstracts, BIOSIS Previews, CAB Abstracts and the Chemical Abstracts Service该刊自 1979 年 1/2 月第 1 卷第 1 期起被（MEDLINE）与（PubMed）收录，并被（SCIE）、（Scopus）、（EMBASE）、（CINAHL）、（Current Contents）、（Biological Abstracts）、（BIOSIS Previews）、（CAB Abstracts）与（CAS）收录。
• In the 2025 Journal Citation Reports it stands in the first quartile of peripheral vascular disease at a 93.5 percentile and it ranks fifth of 100 titles on the journal indicator, keeping the same quartile on the five year indicator在 2025 年版期刊引证报告中，该刊在外周血管疾病类居第一四分位、百分位 93.5，期刊引文指标排名 100 种中第 5 位，五年指标同为第一四分位。

History

• The first issue, volume 1 number 1, appeared in January/February 1979 and set the pattern of the journal by placing basic work beside clinical studies and an association news department, with papers on cardiac output and peripheral resistance in sodium sensitive and sodium resistant rat strains and on the mechanism of angiotensin converting enzyme inhibition by the peptide SQ20,881第 1 卷第 1 期于 1979 年 1/2 月出版，基础研究、临床研究与学会动态栏目并置，奠定该刊格局，首批论文包括钠敏感与钠抵抗大鼠品系的心输出量与外周阻力研究，以及血管紧张素转化酶抑制机制研究。^[1]
• The title began as a bimonthly publication and it took on its present monthly rhythm with the issues of January 1986该刊创刊时为双月刊，自 1986 年 1 月起改为月刊至今。
• In its first year it absorbed an earlier association publication of the same name with the supplement to volume 1 number 3 of 1979, and numbers of the journal were also issued as American Heart Association monographs创刊当年它吸收了同名的学会早期出版物（1979 年第 1 卷第 3 期增刊），该刊的若干期亦曾以美国心脏协会专著（American Heart Association monograph）形式发行。
• Its supplements recorded the meeting literature of the council that drove the field, an annual volume of the Proceedings of the Council for High Blood Pressure Research and biennial proceedings of the scientific meetings of the InterAmerican Society of Hypertension该刊的增刊承载了推动该领域的理事会会议文献，包括《高血压研究理事会会议录》（Proceedings of the Council for High Blood Pressure Research）年度卷，以及美洲高血压学会科学会议的两年一度会议录。
• The association published the journal at its Dallas offices from 1979 and production passed to Lippincott Williams & Wilkins at Hagerstown, Maryland from the issues of January 2002美国心脏协会自 1979 年起在达拉斯的会址出版该刊，2002 年 1 月起出版制作交由（Lippincott Williams & Wilkins）在马里兰州哈格尔斯顿（Hagerstown）承担。
• The journal ran two volumes within 2021 but it settled on a single volume a year from 2022, so the year 2026 is volume 83, while the impact factor moved from 10.19 in 2021 and 9.897 in 2022 to 8.2 in 2024 and 9.8 in 2025该刊在 2021 年内尚出两卷，自 2022 年起固定为每年一卷，2026 年为第 83 卷；影响因子 2021 年为 10.19、2022 年为 9.897、2024 年为 8.2、2025 年为 9.8。

Editors

• Rhian M. Touyz is the editor-in-chief and she writes the periodic update of the journal from that chair, most recently in an account of its direction published in June 2025（Rhian M. Touyz）任主编，并以主编身份定期撰文交代期刊走向，最近一篇发表于 2025 年 6 月。^[2]
• She is executive director and chief scientific officer of the Research Institute of the McGill University Health Centre and holds the chairs of medicine and family medicine at McGill University in Montreal, having moved to Montreal in 2021 after ten years as director of the Institute of Cardiovascular and Medical Sciences and British Heart Foundation professor at the University of Glasgow她任（McGill University Health Centre）研究机构执行主任兼首席科学家，并在蒙特利尔的麦吉尔大学（McGill University）任医学与家庭医学讲席，2021 年转往蒙特利尔，此前十年任格拉斯哥大学（University of Glasgow）心血管医学科学研究所所长兼英国心脏基金会讲席教授。
• Her editorial and society record includes the editorship of Clinical Science, the presidency of the International Society of Hypertension for 2014 to 2016, the presidency of the Canadian Hypertension Society for 2007 to 2008 and the chairing of the councils high blood pressure research committee for 2010 to 2012她的编辑与学会履历包括曾任《临床科学》（Clinical Science）主编，任国际高血压学会（ISH）主席（2014 至 2016 年）、加拿大高血压学会主席（2007 至 2008 年），并曾任美国心脏协会高血压研究委员会主席（2010 至 2012 年）。
• Anna F. Dominiczak edited the journal through the 2010s and marked its thirty fifth anniversary in 2014 with Gregory D. Fink and its fortieth in 2019 with colleagues（Anna F. Dominiczak）在 2010 年代主持该刊，2014 年与（Gregory D. Fink）共同撰文纪念创刊 35 周年，2019 年又与同事撰写 40 周年回顾。^[3]
• The masthead of her editorship was organised with deputy editors, associate editors drawn from hypertension, nephrology and clinical trial research, consulting editors that included Suzanne Oparil and Victor J. Dzau, and a statistical consultant, a layered structure the journal has kept她任内的编委名单采用分层设置：副编辑、来自高血压与肾脏病学及临床试验研究的助理编辑、包括（Suzanne Oparil）与（Victor J. Dzau）在内的顾问编辑，以及统计顾问，该分层体例为其后沿用。